Trends in Immunosuppressive Agent Use for Non-Infectious Uveitis by US Ophthalmologists in Medicare Beneficiaries and Association with Physician-Industry Interactions.
Ocul Immunol Inflamm
; : 1-7, 2023 Nov 02.
Article
en En
| MEDLINE
| ID: mdl-37917798
ABSTRACT
PURPOSE:
To report the trends of immunosuppressive drug use for non-infectious uveitis and explore their relationship with industry payments.METHODS:
A retrospective review of ophthalmologists reimbursed by Medicare for the administration of adalimumab (ADA), repository corticotropin (RCI), methotrexate (MTX), and mycophenolate mofetil (MMF) between 2014 and 2018.RESULTS:
A total of 316 ophthalmologists were reimbursed by Medicare for 1567 ADA, 465 RCI, 1752 MTX, and 12 333 MMF administrations. The number and dollar amount of industry payments were positively associated with ADA and RCI use (P < 0.001). From 2014 to 2018, there was a positive trend in the proportion of ADA (P = 0.007) and RCI (P = 0.007) used and negative trend in the proportion of MMF (P = 0.025) used.CONCLUSION:
From 2014 to 2018, the use of ADA and RCI increased while MMF decreased and MTX remained stable. There was a positive association between ADA and RCI use and physician-industry interactions. A causal relationship is not determined.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
Problema de salud:
1_recursos_humanos_saude
Idioma:
En
Revista:
Ocul Immunol Inflamm
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
OFTALMOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos